静脉注射胺碘酮与普罗帕酮治疗心房颤动的临床对比观察被引量：10

Efficacy comparison of intravenous amiodarone and propafenon for ventricular fibrillation

导出

摘要目的　观察静脉应用胺碘酮与普罗帕酮对阵发性快速心房颤动 (房颤 )的疗效。方法　选择 4 9例患者按就诊顺序随机分为两组 ,胺碘酮组 (2 5例 ) :胺碘酮 15 0mg+生理盐水 10ml,静脉注射 ,10分钟注射完毕 ;普罗帕酮组 (2 4例 ) :普罗帕酮 70mg +生理盐水 10ml,静脉注射 ,5～ 10分钟注射完毕。观察 10～ 2 0分钟若未转复可重复应用 ,最大累积量胺碘酮为 4 5 0mg ,普罗帕酮为 2 10mg。结果　转复率 :胺碘酮组 76 % (19/ 2 5 ) ,普罗帕酮组 75 % (18/2 4 ) ,两组转复率比较差异无统计学意义 (χ2 =0 .0 0 4 2 ,P >0 .0 5 )。转复时间 :胺碘酮组 (4 8.1± 15 .9)分钟 ,普罗帕酮组 (38.7± 14 .9)分钟 ,两组比较差异有统计学意义 (t=2 .13,P <0 .0 5 )。结论　胺碘酮和普罗帕酮对阵发性快速房颤均有较高的转复率。 Objective To evaluate the efficacy of intravenous amiodarone and propafenon for atrial paroxysmal fibrillation(AF).Methods 49 patients were divided into 2 groups randomly.Group 1(25 patients) was treated intravenously with 150 mg amiodarone and 10 ml normal saline within 10 min. Group 2 (24 patients) was treated intravenously with 70 mg propafenon and 10 ml normal saline within 5 10 min.After 10 20 minutes,if the resuscitation was not good,the above intravenous injections can be given again,the maximum accumulated dose was 450 mg(AM) and 210 mg (propafenon).Results The resuscitation rate of 2 groups was 76%(19/25) and 75%(18/24),respectively.Compare the resuscitation, χ 2 = 0.0042 , P > 0.05 .The resuscitation duration for the two groups was ( 48.1 ± 15.9 ) min and ( 38.7 ± 14.9 ) min respectively, t = 2.13 , P < 0.05 .Conclusion Both amiodarone and propafenon have a high efficacy for treatment of AF,but for the resuscitation duration,propafenon was shorter.

作者杨志平扈秀丽

机构地区新乡市中心医院心内科新乡市第一人民医院

出处《临床荟萃》 CAS 北大核心 2003年第15期855-857,共3页 Clinical Focus

关键词胺碘酮普罗帕酮心房颤动 amiodarone propafenon atrial fibrillation

分类号 R541.075 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Cabin H S,Clubb K S,Hall C,d a1.Risk for systemic embolization of atrial fibrillation without mitral stenosis[J].Am J Cardiol,1990,65(16):1112-一1116.
2Petersen P,Godtferdsen J. Embolic complications in paroxysmal atrial fibrillation[J].Stroke,1986,17(4):622—626.
3Levy S,Breithardt G,Campbell R W, et al . Atrial fibrillation:current knowledge and recommendations for management.Working Group on Arrhythmial of the European Society of Cardiology[J]. Eur Heart J,1998,19(9) :1294-1320.
4Ricard P, Levy S, Trlgano J, et al . Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation[J]. Am J Cardiol, 1997,79(6) :815-816.
5Prystowsky E N. Management of atrial fibrillation: therapeutic options and clinical decisions [J]. Am J Cardiol, 2000, 85(10A): 3D-11D.
6Lewis R V, Mcmurray J, McDevitt D G. Effects of atenolol,verapamil,and xamoterol on heart rate and exercise tolerance in digitalized patients with chronic atrial fibrillation[J]. J Cardiovasc Pharmacol, 1989,13 ( 1 ) : 1-6.
7Kreiss Y, Sidi Y, Gur H. Efficacy and safety of intravenous amiodarone in recent onset atrial fibrillation, experience in patients admitted to a general internal medicine department[J]. Postgrad Med J, 1999,75(2) :278-281.
8Reiffel J A. Intravenous amiodarone in the management of atrial fibrillation[J]. J Cardiovase Pharmacol Ther,1999,4(4):199-204.
9Bellandi F, Cantini F, Pedone T, et al. Effectiveness of intravenous propafenone for conversion of recent--onset atrial fibrillation:a placebocontrolled study[J]. Clin Cardiol,1995,18(11):631-634.
10Fresco C, Proclemer A, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized,placebo-controlled, double-blind, multicemer clinical trial.Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators[J]. Clin Cardinl. 1996. 19(5): 400-412.